The nature of the merger with Ireland-based Allergan has renewed debate over corporate tax avoidance. Heres why such deals often meet political oppositionUS drugs giant Pfizer is merging with Irish-headquartered Allergan in a record-breaking $155bn (£100bn) deal. It is the largest so-called tax inversion dash to date, and will bring enormous tax savings to Pfizer as it shifts its headquarters from the US to tax-light Ireland. Related: Pfizer's $155bn takeover of Allergan set to prompt tax row Continue reading...
Source: theguardian.com